We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-7.32%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.93B
AUM Growth
-$321M
Cap. Flow
-$98.8M
Cap. Flow %
-5.11%
Top 10 Hldgs %
70.83%
Holding
57
New
3
Increased
7
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$153M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$19.4M
3
FOLD
Amicus Therapeutics
FOLD
+$5.75M
4
PHVS icon
Pharvaris
PHVS
+$5.27M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$4.32M

Top Sells

Rank Stock Value
1
INGN icon
Inogen
INGN
+$61.5M
2
HRMY icon
Harmony Biosciences
HRMY
+$44.5M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$36M
4
INZY
Inozyme Pharma
INZY
+$31.8M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 57.28%
2 Financials 8.56%
3 Technology 7.59%
4 Consumer Discretionary 1.65%
5 Communication Services 1.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$646B
$429M 22.21%
1,933,900
– –
BN icon
2
Brookfield
BN
$102B
$166M 8.56%
5,739,379
+33,570
+0.6% +$980K
BSX icon
3
Boston Scientific
BSX
$68.4B
$150M 7.77%
+3,463,577
New +$153M
AAPL icon
4
Apple
AAPL
$4.97T
$147M 7.59%
1,037,404
– –
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$116M 6.01%
2,050,446
-595,000
-22% -$36M
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.28B
$92.7M 4.8%
5,587,207
– –
CYT
7
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$84.9M 4.39%
4,840,413
– –
NKTX icon
8
Nkarta
NKTX
$152M
$77.7M 4.02%
2,793,864
– –
BOLT icon
9
Bolt Biotherapeutics
BOLT
$7.4M
$57M 2.95%
225,200
– –
MIRM icon
10
Mirum Pharmaceuticals
MIRM
$6.56B
$48.7M 2.52%
2,445,147
– –
INGN icon
11
Inogen
INGN
$174M
$46.5M 2.41%
1,079,320
-1,000,000
-48% -$61.5M
ALGS icon
12
Aligos Therapeutics
ALGS
$26.3M
$40.6M 2.1%
104,583
– –
BABA icon
13
Alibaba
BABA
$276B
$31.8M 1.65%
214,827
– –
CABO icon
14
Cable One
CABO
$237M
$28.8M 1.49%
15,873
-10,025
-39% -$19.6M
VERV
15
DELISTED
Verve Therapeutics
VERV
$28.2M 1.46%
600,000
-193,265
-24% -$11.4M
VECT
16
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$27.2M 1.41%
3,522,019
– –
SPRB
17
Spruce Biosciences
SPRB
$114M
$27.1M 1.4%
60,191
– –
OKUR
18
OnKure Therapeutics
OKUR
$160M
$25.6M 1.32%
343,038
– –
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
$24.4M 1.26%
2,560,211
+562,331
+28% +$5.75M
IOVA icon
20
Iovance Biotherapeutics
IOVA
$2.04B
$20.6M 1.07%
836,518
+161,358
+24% +$3.8M
BPMC
21
DELISTED
Blueprint Medicines
BPMC
$20.3M 1.05%
197,000
– –
GRTX
22
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$19.9M 1.03%
2,459,021
– –
LVTX
23
DELISTED
LAVA Therapeutics
LVTX
$19.7M 1.02%
3,327,312
– –
INSM icon
24
Insmed
INSM
$22.4B
$19.2M 0.99%
695,840
– –
SPNE
25
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$17.3M 0.89%
1,099,478
-14,368
-1% -$246K
1
2 3

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Novo Holdings A/S's Q3 2021 Portfolio in Review

As of Q3 2021, Novo Holdings A/S held 57 positions worth $1.93B, down 14% from $2.25B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Novo Holdings A/S withdrew a net $98.8M in Q3 2021, closing 8 positions and reducing 11 holdings. Its most notable exit was Inozyme Pharma, an estimated $31.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 61% a quarter earlier, followed by Financials and Technology.

Against the trend, Novo Holdings A/S opened a new position in Boston Scientific worth $150M.

  • Novo Holdings A/S's largest Q3 2021 buy was Boston Scientific: 3,463,577 shares worth $150M.
  • Novo Holdings A/S added most to Amicus Therapeutics in Q3 2021, an estimated $5.75M increase.
  • Novo Holdings A/S's biggest Q3 2021 reduction was Inogen, cutting an estimated $61.5M.
  • Novo Holdings A/S fully exited Inozyme Pharma in Q3 2021, selling an estimated $31.8M.
  • Novo Holdings A/S's ten largest holdings make up 71% of its $1.93B portfolio in Q3 2021.
  • Novo Holdings A/S opened 3 new positions and closed 8 in Q3 2021.
  • Novo Holdings A/S's portfolio value fell 14% quarter-over-quarter to $1.93B.

Based on Novo Holdings A/S's 13F filing for Q3 2021, filed 15 Nov 2021.